Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen (Q33222362)

24 July 2017

Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen (English)

1 reference

24 July 2017

0 references

1 reference

Doris Apt

1

1 reference

24 July 2017

Kanakatte Raviprakash

2

1 reference

24 July 2017

Alice Brinkman

3

1 reference

24 July 2017

Andrey Semyonov

4

1 reference

24 July 2017

Shumin Yang

5

1 reference

24 July 2017

Craig Skinner

6

1 reference

24 July 2017

Lori Diehl

7

1 reference

24 July 2017

Richard Lyons

8

1 reference

24 July 2017

Kevin Porter

9

1 reference

24 July 2017

Juha Punnonen

10

1 reference

24 July 2017

language of work or name

English

0 references

publication date

10 August 2005

1 reference

24 July 2017

1 reference

24 July 2017

24

1 reference

24 July 2017

3

1 reference

24 July 2017

335-344

1 reference

Research on dengue during World War II

24 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Pathogenesis of dengue: challenges to molecular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Dengue: the risk to developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Development of new vaccines against dengue fever and Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Live attenuated tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

DNA vaccines--back in the saddle again?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Applications of DNA shuffling to pharmaceuticals and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Evolution of a cytokine using DNA family shuffling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Molecular breeding of viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Optimized expression and specific activity of IL-12 by directed molecular evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

DNA shuffling of a family of genes from diverse species accelerates directed evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.100

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.07.100

1 reference

24 July 2017

1 reference